United Therapeutics Corp (NASDAQ:UTHR) disclosed that Paul A. Mahon, its Executive Vice President and General Counsel, sold company common stock valued at approximately $4.69 million on November 19, 2026. The transactions were carried out under a pre-arranged 10b5-1 trading plan, a structure designed to allow insiders to execute trades on a predetermined schedule.
According to the filing, Mahon disposed of 8,300 shares at prices ranging from $554.50 to $577.31 per share, generating total proceeds of $4,690,228. Before the sales, he acquired the same number of shares by exercising stock options at an exercise price of $146.03 per share, for a total acquisition value of $1,212,049. Both the option exercise and the subsequent sales were executed under a 10b5-1 plan established on August 11, 2025.
Following these transactions, Mahon directly holds 45,172 shares of United Therapeutics common stock.
The insider sale comes as United Therapeutics trades near $559, with the biotechnology company maintaining a market capitalization of $23.81 billion. According to an analysis, the stock currently appears overvalued relative to its Fair Value estimate. Despite the insider transaction, the analysis highlights that the company holds more cash than debt on its balance sheet and boasts impressive gross profit margins of 86%.
In other recent news, United Therapeutics reported record third-quarter revenue of $832.5 million, surpassing Wall Street’s estimate of $785.44 million. Despite this, the company’s earnings per share fell short, registering at $5.71 compared to the forecasted $6.21. The revenue growth was primarily driven by strong demand for Tyvaso, with its revenue alone reaching $503.8 million, up 11% from the previous quarter and 5% year-over-year, exceeding consensus estimates of $458.6 million.
Raymond James responded by raising its price target for United Therapeutics to $720, maintaining an Outperform rating. Wells Fargo also adjusted its price target to $703, citing the competitive landscape concerning Yutrepia in ILD and PAH markets. H.C. Wainwright increased its price target to $660, highlighting the company’s multi-route pulmonary hypertension platform. These developments reflect ongoing confidence in United Therapeutics’ commercial strategies and product demand.